carmustine has been researched along with HIV Coinfection in 3 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The experimental programme was safe and active in a multicentre setting, with only two episodes of grade 4 non-haematological toxicity (hepatotoxicity and mucositis), and no cases of systemic fungal infections; two patients died of toxicity (bacterial infections)." | 3.01 | A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial. ( Allione, B; Calimeri, T; Cattaneo, C; Donadoni, G; Facchetti, F; Ferrari, D; Ferreri, AJM; Foppoli, M; Fumagalli, L; Lleshi, A; Pecciarini, L; Ponzoni, M; Re, A; Rigacci, L; Rossi, G; Sassone, M; Spina, M; Verga, L, 2021) |
| "Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas." | 1.48 | Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. ( Baars, JW; Brouwer, R; Chamuleau, MED; de Jong, D; de Wreede, LC; Demandt, AMP; Doorduijn, JK; Hardi, L; Kersten, MJ; Kluin, PM; Nijland, M; Oosten, LEM; Siemes, C; Smeekes, OS; Stevens, WBC; Thielen, FW; Uyl-de Groot, CA; van Imhoff, GW; Veelken, H, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreri, AJM | 1 |
| Cattaneo, C | 1 |
| Lleshi, A | 1 |
| Verga, L | 1 |
| Allione, B | 1 |
| Facchetti, F | 1 |
| Ponzoni, M | 1 |
| Foppoli, M | 1 |
| Ferrari, D | 1 |
| Rigacci, L | 1 |
| Pecciarini, L | 1 |
| Donadoni, G | 1 |
| Fumagalli, L | 1 |
| Sassone, M | 1 |
| Calimeri, T | 1 |
| Rossi, G | 1 |
| Spina, M | 1 |
| Re, A | 1 |
| Oosten, LEM | 1 |
| Chamuleau, MED | 1 |
| Thielen, FW | 1 |
| de Wreede, LC | 1 |
| Siemes, C | 1 |
| Doorduijn, JK | 1 |
| Smeekes, OS | 1 |
| Kersten, MJ | 1 |
| Hardi, L | 1 |
| Baars, JW | 1 |
| Demandt, AMP | 1 |
| Stevens, WBC | 1 |
| Nijland, M | 1 |
| van Imhoff, GW | 1 |
| Brouwer, R | 1 |
| Uyl-de Groot, CA | 1 |
| Kluin, PM | 1 |
| de Jong, D | 1 |
| Veelken, H | 1 |
| Roberts, RL | 1 |
| Aroda, VR | 1 |
| Ank, BJ | 1 |
1 trial available for carmustine and HIV Coinfection
| Article | Year |
|---|---|
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2021 |
2 other studies available for carmustine and HIV Coinfection
| Article | Year |
|---|---|
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustin | 2018 |
N-acetylcysteine enhances antibody-dependent cellular cytotoxicity in neutrophils and mononuclear cells from healthy adults and human immunodeficiency virus-infected patients.
Topics: Acetylcysteine; Adolescent; Adult; Antibody-Dependent Cell Cytotoxicity; Antioxidants; Carmustine; C | 1995 |